Low molecular weight fucoidan ameliorates the inflammation and glomerular filtration function of diabetic nephropathy

Diabetic nephropathy (DN) is a type of serious microangiopathy that is caused by diabetes mellitus (DM). It is the most common cause of chronic renal failure and end-stage renal disease, and it severely affects patients' quality of life. This work aims to study the effect and mechanism of low molecular weight fucoidan (LMWF) on streptozotocin (STZ)-induced DN. The experimental results showed that LMWF prevented weight loss in DN rats, significantly reduced the levels of biochemical indexes in blood and urine samples, and also lowered hyaluronic acid (HA) levels and advanced glycosylation end product-specific receptor (AGER) levels in DN rats. LMWF maintained the structural integrity of glomerular basement membrane (GBM) and glomerulus, improved the glomerular filtration function, protected glycosaminoglycan from abnormal degrading, prevented advanced glycosylation end product (AGE) from being generated and accumulating, and also alleviated inflammatory response in DN rats. LMWF could obviously ameliorate and slow the development and progression of DN in rats.